ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
14 hedge funds and large institutions have $2.15M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
7% less funds holding
Funds holding: 15 → 14 (-1)
30.02% less ownership
Funds ownership: 48.55% → 18.52% (-30%)
74% less capital invested
Capital invested by funds: $8.44M → $2.15M (-$6.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$323K |
| 2 |
CG
Colony Group
Boston,
Massachusetts
|
+$248K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$176K |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$120K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$16.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
-$6.92M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$312K |
| 3 |
LPL Financial
San Diego,
California
|
-$21.2K |
| 4 |
Morgan Stanley
New York
|
-$6.88K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.93K |
CNCR Hedge Fund Activity: Q2 2023 in Review
14 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2023, worth a combined $2.15M — down 74% from $8.44M a quarter earlier.
Fund positioning in CNCR was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $323K. The largest seller was BCWM LLC, exiting entirely with an estimated $6.92M sold.
- 14 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2023, down from 15 in Q1 2023.
- Funds reported $2.15M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2023, down 74% quarter-over-quarter.
- 2 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2023 was Susquehanna International Group, an estimated $323K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2023 was BCWM LLC, an estimated $6.92M sold.
Based on aggregated 13F filings for Q2 2023.